Trials / Unknown
UnknownNCT04756323
A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase II Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,000 (actual)
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is a randomized, double-blinded, and placebo controlled phase Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | medium dosage inactivated SARS-CoV-2 vaccine | medium dosage |
| BIOLOGICAL | high dosage inactivated SARS-CoV-2 vaccine | high dosage |
| BIOLOGICAL | Placebo | placebo |
Timeline
- Start date
- 2020-10-27
- Primary completion
- 2021-06-30
- Completion
- 2022-02-28
- First posted
- 2021-02-16
- Last updated
- 2021-02-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04756323. Inclusion in this directory is not an endorsement.